Please assess the completion status of the following clinical trial:

Trial Title: Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical or molecular diagnosis of Neurofibromatosis Type 1~2. Plexiform neurofibroma that is progressive OR causing significant morbidity.~3. Measurable disease amenable to volumetric MRI imaging defined as lesion seen on at least 3 consecutive MRI slices and at least 3 mL in volume. Select tumors \<3 cm may be eligible on review.~4. Central review or MRI required prior to enrollment.~5. Age ≥ 3 years of age at the time of study entry. Subjects ≥ 16 years will be enrolled in Cohort A. Subjects 3 - 15 years will be enrolled in Cohort B.~6. Performance Level Karnofsky ≥ 50%. Subjects unable to walk because of paralysis, but up in a wheel chair will be considered ambulatory for purpose of assessing performance score.~7. Complete resection of plexiform neurofibroma is not feasible or if subject refuses surgery.~8. Fully recovered from acute toxic effects of all prior chemotherapy or radiotherapy.~9. No myelosuppressive chemotherapy within 4 weeks of study entry.~10. At least 7 days since completion of hematopoietic growth factors.~11. At least 14 days since completion of biologic agent.~12. At least 4 weeks since receiving any investigational drug.~13. Physiologic or stress doses of steroids allowed in patients with endocrine deficiencies.~14. At least 6 months from radiation therapy to index tumor and at least 6 weeks from radiation to areas outside of index plexiform neurofibroma.~15. At least 3 months from major surgery or at least 1 month from minor surgery. No major surgery anticipated within 3 months of enrollment.~16. Adequate bone marrow function.~17. Adequate renal function.~18. Adequate liver function.~19. Blood pressure within upper limit of normal.~Exclusion Criteria:~1. Active optic glioma or other low-grade glioma requiring treatment with chemotherapy or radiation therapy.~2. Malignant glioma, malignant peripheral nerve sheath tumor, or other malignancy requiring treatment in the last 12 months.~3. Dental braces or prosthesis that interferes with volumetric analysis of the neurofibroma(s).~4. Unable to swallow tablets.~5. Women who are pregnant or breast-feeding.~6. Subjects of reproductive potential who have not agreed to use effective contraception.~7. Subject has not recovered to baseline or CTCAE ≤ Grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs).~8. Subject requires anticoagulants. Low dose aspirin, low-dose warfarin, and prophylactic low molecular weight heparin are permitted.~9. Concomitant treatment of strong CYP3A4 inducers or inhibitors.~10. History of noncompliance to medical regimens~11. A known history of HIV seropositivity or known immunodeficiency. HIV testing will not be required as part of this trial, unless HIV is clinically suspected.~12. Impairment of gastrointestinal function or gastrointestinal disease that may affect the absorption of cabozantinib. (e.g. ulcerative disease, malabsorption syndrome, or small bowel resection). Nasogastric tube (NG) tube is allowed.~    * Any of the following within 28 days before the first dose of study treatment:~      1. intra-abdominal tumor/metastases invading GI mucosa~     2. active peptic ulcer disease~     3. inflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis~     4. malabsorption syndrome~   * Any of the following within 6 months before the first dose of study treatment:~      1. abdominal fistula~     2. gastrointestinal perforation~     3. bowel obstruction or gastric outlet obstruction~     4. intra-abdominal abscess. Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating study treatment even if abscess occurred more than 6 months before the first dose of study treatment.~   * Other disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement within 3 months before the first dose of study therapy~13. Patients who have an uncontrolled infection.~14. Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment~15. Hemoptysis of ≥0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment~16. Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment~17. Radiographic evidence of cavitating pulmonary lesion(s).~18. Concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (e.g. uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, chronic liver or renal disease, active upper GI tract ulceration)~19. Cardiovascular disorders including:~    * Congestive heart failure (CHF): New York Heart Association (NYHA) Class III (moderate) or Class IV (severe) at the time of screening~   * Concurrent uncontrolled hypertension defined as sustained BP \> 140 mm Hg systolic, or \> 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days before the first dose of study treatment~   * Any history of congenital long QT syndrome~   * Baseline heart-rate corrected QT (QTc) interval \>470 msec in women and \>450 msec in men~   * Concomitant treatment with medications that prolong the QT interval and have a known risk of Torsades de Pointes is not contraindicated, but should be avoided if possible and will require more frequent EKG monitoring.~   * Any of the following within 6 months before the first dose of study treatment:~      1. unstable angina pectoris~     2. clinically-significant cardiac arrhythmias~     3. stroke (including transient ischemic attack (TIA), or other ischemic event)~     4. myocardial infarction~     5. thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter (e.g. vena cava filter) are not eligible for this study)~20. Other clinically significant disorders such as:~    * Active infection requiring systematic treatment within 28 days before the first dose of study treatment~   * Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment~   * History of organ transplant~   * Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment~21. Complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of study treatment irrespective of time from surgery.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Agent XL184 (Cabozantinib) (Type: EXPERIMENTAL): Cohort A (≥ 16 years - closed to accrual): Starting cabozantinib of 40 mg daily by mouth per cycle. Duration of each cycle is 28 days. Subjects will dose escalate after 2 cycles to 60 mg based on dose tolerability. Subjects who do not tolerate 40 mg will dose reduce to 20 mg. Doses will be capped at 60 mg.~Cohort B (3 - 15 years). The starting cabozantinib dose is 30 mg/m2/day by mouth per cycle. Duration of each cycle is 28 days. Subjects will dose escalate after 2 cycles to 40 mg/m2/day based on dose tolerability. Subjects who do not tolerate 30 mg/m2/day will dose reduce to 23 mg/m2/day. Doses will be capped at 60 mg/day max daily dose~Each cohort will enroll up to 24 evaluable subjects with a target minimum of 17 evaluable subjects per cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete